AMGN Stock Recent News
AMGN LATEST HEADLINES
Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011, offers reliable income and a healthy payout ratio. Robust R&D pipeline in obesity, cardiovascular, and oncology, along with strong financials, positions Amgen for long-term growth and stability. Despite underperforming the S&P 500, Amgen's focus on high-growth areas and promising new drugs provides a compelling growth narrative.
Amgen (AMGN) closed at $322.67 in the latest trading session, marking a +1.12% move from the prior day.
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Amgen, Inc. for Data Breach.
The Investment Committee debate the latest Calls Of The Day.
Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.
In an investor update on Tuesday, Amgen Inc AMGN released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio, including Eylea, Dupixent, and Libtayo, and a robust investigational pipeline. Despite legal setbacks from Amgen's Eylea biosimilar, the legal battle continues, and REGN's patents protect EYLEA HD until at least 2037. Moreover, Dupixent and Libtayo remain strong growth drivers, contributing significantly to Regeneron's revenue with expanding approvals and indications.
Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment for a skin condition known as atopic dermatitis.
THOUSAND OAKS, Calif. , Sept. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease (TED) by Japan's Ministry of Health, Labour and Welfare (MHLW).
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.